Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;150(5):467-474.
doi: 10.1111/jnc.14698. Epub 2019 Apr 23.

Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions

Lauren Walker  1 , Leonidas Stefanis  2   3 , Johannes Attems  1
Affiliations
Free article
Review

Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions

Lauren Walker et al. J Neurochem. 2019 Sep.
Free article

Abstract

Lewy body diseases share clinical, pathological, genetic and biochemical signatures, and are regarded as a highly heterogeneous group of neurodegenerative disorders. Inclusive of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), controversy still exists as to whether they should be considered as separate disease entities or as part of the same disease continuum. Here we discuss emerging knowledge relating to both clinical, and neuropathological differences and consider current biomarker strategies as we try to improve our diagnostic capabilities and design of disease modifying therapeutics for this group of debilitating neurodegenerative disorders. This article is part of the Special Issue "Synuclein".

Keywords: Parkinson's disease; Parkinson's disease dementia; clinical heterogeneity; dementia with Lewy bodies; neuropathology.

PubMed Disclaimer

References

    1. Alafuzoff I., Arzberger T., Al-Sarraj S. et al. (2008) Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol. (Zurich, Switzerland) 18, 484-496.
    1. Attems J. and Jellinger K. (2013) Neuropathology, in Oxford Textbook of Old Age Psychiatry, (Dening T. T. and Alan Thomas J. ed.), pp. 87-105. Oxford Unversity Press, New York.
    1. Attems J., Neltner J. H. and Nelson P. T. (2014) Quantitative neuropathological assessment to investigate cerebral multi-morbidity. Alzheimer's Res. Therapy 6, 85.
    1. Badiola N., de Oliveira R. M., Herrera F. et al. (2011) Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS ONE 6, e26609.
    1. Ballard C., Ziabreva I., Perry R., Larsen J. P., O'Brien J., McKeith I., Perry E. and Aarsland D. (2006) Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67, 1931-1934.

Publication types

MeSH terms